Not Yet Recruiting
OBSERVATIONAL
NCT04901104
Long-term Prognosis of Patients With Sepsis After Immunotherapy
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy. Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.
Interventions
Name:
Thymosin Alpha1
Type:
DRUG
Description:
Drug interventions have been done in previous clinical studies
Primary Outcomes
Measure:
three years mortality
TimeFrame:
3 years
Description:
Mortality rate of patients treated with thymosin α1 or placebo within 3 years
Trial Information
NCT ID
NCT04901104
Status
Not Yet Recruiting
Study Type
OBSERVATIONAL
Sponsor
Sun Yat-sen University
Last Updated
December 15, 2025